このページの翻訳は実験的なもので、現在開発中です。お待ちしております

BriaCell Therapeutics 将来の成長

Future 基準チェック /06

BriaCell Therapeuticsの収益は年間15.4%で減少すると予測されていますが、年間収益は年間70.7%で増加すると予想されています。EPS は年間33.6%で増加すると予想されています。

主要情報

-15.0%

収益成長率

37.0%

EPS成長率

Biotechs 収益成長	41.6%
収益成長率	65.0%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	23 Sep 2024

今後の成長に関する最新情報

更新なし

Recent updates

We Think BriaCell Therapeutics (TSE:BCT) Needs To Drive Business Growth Carefully

Dec 01

We're Not Very Worried About BriaCell Therapeutics' (TSE:BCT) Cash Burn Rate

May 07

We Think BriaCell Therapeutics (TSE:BCT) Can Afford To Drive Business Growth

Feb 05

業績と収益の成長予測

TSX:BCT - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
7/31/2027	10	-50	-78	N/A	1
7/31/2026	N/A	-40	-58	N/A	1
7/31/2025	N/A	-31	-45	N/A	2
7/31/2024	N/A	-19	-9	N/A	2
4/30/2024	N/A	-6	-31	-31	N/A
1/31/2024	N/A	-13	-31	-31	N/A
10/31/2023	N/A	-13	-28	-28	N/A
7/31/2023	N/A	-20	-24	-24	N/A
4/30/2023	N/A	-18	-16	-16	N/A
1/31/2023	N/A	-23	-16	-16	N/A
10/31/2022	N/A	0	-14	-14	N/A
7/31/2022	N/A	-27	-12	-12	N/A
4/30/2022	N/A	-42	-11	-11	N/A
1/31/2022	N/A	-30	-12	-12	N/A
10/31/2021	N/A	-41	-9	-9	N/A
7/31/2021	N/A	-14	-8	-8	N/A
4/30/2021	N/A	2	-6	-6	N/A
1/31/2021	N/A	-2	-1	-1	N/A
10/31/2020	N/A	-3	-1	-1	N/A
7/31/2020	N/A	-4	-1	-1	N/A
4/30/2020	N/A	-4	-1	-1	N/A
1/31/2020	N/A	-5	-3	-3	N/A
10/31/2019	N/A	-5	-4	-4	N/A
8/1/2019	N/A	-5	-4	-4	N/A
4/30/2019	N/A	-5	-4	-4	N/A
1/31/2019	N/A	-5	-4	-4	N/A
10/31/2018	N/A	-4	-4	-4	N/A
7/31/2018	N/A	-4	-4	-4	N/A
4/30/2018	N/A	-3	-3	-3	N/A
1/31/2018	N/A	-3	N/A	-3	N/A
10/31/2017	N/A	-3	N/A	-2	N/A
7/31/2017	N/A	-3	N/A	-2	N/A
4/30/2017	N/A	-2	N/A	-2	N/A
1/31/2017	N/A	-1	N/A	-1	N/A
10/31/2016	N/A	-2	N/A	-1	N/A
7/31/2016	N/A	-2	N/A	-1	N/A
4/30/2016	N/A	-2	N/A	-1	N/A
1/31/2016	N/A	-2	N/A	-1	N/A
10/31/2015	N/A	-3	N/A	-1	N/A
7/31/2015	N/A	-3	N/A	-1	N/A

アナリストによる今後の成長予測

収入対貯蓄率: BCT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: BCT今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: BCT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: BCT来年は収益がないと予測されています。

高い収益成長: BCT来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: BCTの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

BriaCell Therapeutics 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

New major risk - Share price stability

BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients

New major risk - Financial data availability

New major risk - Shareholder dilution

BriaCell Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $8.50425 million.

BriaCell Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $8.50425 million.

BriaCell Therapeutics Corp. Announces Positive Overall Survival Data of its Phase 2 Clinical Study of Bria-IMT in Combination with an Immune Check Point Inhibitor

BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+ for Prostate Cancer

BriaCell Therapeutics Receives Deficiency Letter from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

New major risk - Share price stability

BriaCell Therapeutics Corp. Quadruples Progression Free Survival (Pfs) in Patient with "Eye-Bulging" Metastatic Breast Cancer

BriaCell Therapeutics Receives Letter from Nasdaq Due to Non-Compliance with the Minimum Market Value of Listed Securities Requirement Pursuant to Nasdaq Listing Rule 5550(b)(2)

Briacell Therapeutics Corp. Presents Clinical Efficacy Data At ASCO 2024

BriaCell Therapeutics Corp. Initiates Patient Enrollment in First-In-Human Study of Bria-Ots in Advanced Metastatic Breast Cancer

New minor risk - Shareholder dilution

Independent Director recently bought CA$2.7m worth of stock

BriaCell Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $4.80586 million.

BriaCell Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $5 million.

BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer

New minor risk - Share price stability

New major risk - Negative shareholders equity

BriaCell Therapeutics Corp. Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case

Briacell Therapeutics Corp. Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates Gmp Manufacturing

BriaCell Therapeutics Corp. Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients

BriaCell Therapeutics Corp. Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate Refractory Patient Subset

BriaCell Therapeutics Corp. Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS

BriaCell Therapeutics Corp., Annual General Meeting, Jan 30, 2024

We Think BriaCell Therapeutics (TSE:BCT) Needs To Drive Business Growth Carefully

BriaCell Therapeutics Corp. Announces Anew Remarkable Responder in Phase 2 Study of the Bria-IMT Combination Regimen

BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ IND

New major risk - Financial position

BriaCell Therapeutics Corp. Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate

BriaCell Therapeutics Corp. Initiates Pivotal Phase 3 Study of Bria-Imt™ in Advanced Metastatic Breast Cancer

BriaCell Therapeutics Corp. Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer

BriaCell Therapeutics Corp. completed the Spin-Off of 33.33% stake in Pre-Clinical Assets of BriaCell Therapeutics Corp.

Briacell Receives National Cancer Institute Grant to Advance Its Bria-Ots™ Immunotherapy for Cancer

FDA Approves BriaCell’s Pivotal Registrational Study Design in Advanced Metastatic Breast Cancer

BriaCell Therapeutics Corp. Announces Positive End of Phase II Meeting with the FDA for Bria-IMT™ Combination in Advanced Metastatic Breast Cancer

Independent Chairman of the Board recently bought CA$160k worth of stock

BriaCell Therapeutics Corp., Annual General Meeting, Jan 24, 2023

BriaCell Therapeutics Corp. Reports Positive Breast Cancer Efficacy Data with Bria-IMT™ Immunotherapy Treatment at SITC Annual Meeting

BriaCell Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation Progressing

BriaCell Therapeutics Corp. Announces New Clinical Trial Site to Bring Novel Cancer Treatments to Advanced Breast Cancer Patients

BriaCell Therapeutics Corp. Secures License for A Promising Novel Anti-Cancer Agent

We're Not Very Worried About BriaCell Therapeutics' (TSE:BCT) Cash Burn Rate

BriaCell Therapeutics Corp. Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy

BriaCell Advances Preparatory Work for New Bria-OTS Breast Cancer Clinical Trial

High number of new directors

BriaCell Therapeutics Corp. Adds Two Clinical Trial Sites to Accelerate Patient Enrollment

BriaCell Therapeutics Corp. Appoints Alexander Kharazi to Its Scientific Advisory Board

Director recently bought CA$549k worth of stock

Briacell Therapeutics Corp. Appoints Giuseppe Del Priore as Chief Medical Officer

Director recently bought CA$451k worth of stock

We Think BriaCell Therapeutics (TSE:BCT) Can Afford To Drive Business Growth

BriaCell Therapeutics Corp.(TSXV:BCT) dropped from S&P/TSX Venture Composite Index

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

High number of new and inexperienced directors

Investor sentiment improved over the past week

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Investor sentiment improved over the past week

Investor sentiment improved over the past week

BriaCell Therapeutics Corp. Announces Phase I/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment

Investor sentiment improved over the past week

Briacell Therapeutics Expands Breast Cancer Platform Technology into Prostate, Melanoma, and Lung Cancers

BriaCell Therapeutics Corp. announced that it has received $27.195924 million in funding

BriaCell Therapeutics Corp. announced that it expects to receive $27.195924 million in funding

Briacell Therapeutics Corp. Provides an Update on the Overall Survival (Os) Data on Its Previously Disclosed Advanced Breast Cancer Patients

CEO, President & Director recently bought CA$325k worth of stock

BriaCell Therapeutics Corp., Annual General Meeting, May 18, 2021

BriaCell Therapeutics Corp's Common Shares Deleted from Other OTC

New 90-day high: CA$7.99